ESC Congress 2022 (Photo by Kyle LaHucik)
#ESC22: CinCor CMO’s 17-year journey in bringing a new hypertension drug to market continues
BARCELONA — Sixteen years ago, Mason Freeman was “very disappointed.” A first-in-human study of an aldosterone synthase inhibitor, or ASI, had done what it was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.